GRAIL Galleri (Multi-Cancer Early Detection)

The Galleri test represents a fundamental shift in cancer screening philosophy — from screening for individual cancers one at a time (mammogram for breast, colonoscopy for colon) to screening for dozens of cancers simultaneously through a single blood draw. It works by detecting cell-free DNA (cfDNA) fragments that are shed by tumor cells into the bloodstream and analyzing their methylation patterns to determine whether a cancer signal is present and, if so, where in the body it likely originates.

The test's greatest value lies in its ability to screen for cancers that currently have no standard screening test — including pancreatic, ovarian, liver, bile duct, stomach, and esophageal cancers. These cancers are typically caught late and carry poor prognoses. Standard screening only covers five cancer types (breast, cervical, colorectal, lung, prostate), leaving over 70% of cancer deaths from unscreened cancers.

Important limitations exist. Sensitivity for early-stage (Stage I) cancers is relatively low (~17%), improving significantly for later stages (Stage III: ~77%, Stage IV: ~90%). This means a negative Galleri test does not guarantee the absence of early cancer. The test's specificity is high (99.5%), resulting in a low false positive rate. Galleri should complement, not replace, standard cancer screening. Most longevity physicians recommend annual Galleri testing beginning at age 50, or earlier for those with significant family history or elevated cancer risk.